ReviewFrontiers in pharmacology2018
Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases.
Review in Frontiers in pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Anti-cancer activity of guggulsterone by modulating apoptotic markers: a systematic review and meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Effects of different parts of Boswellia dalzielii Hutch extracts on key enzymes associated with brain function - in vitro.BMC complementary medicine and therapies · 2026Article
- A bibliometric and critical trend analysis of the anti-cancer potential of Withania somnifera during 2000-2024.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Harnessing phytochemicals for engineering health solutions.Human genomics · 2026Review
- Betulinic Acid and Betulin Suppress Melanoma Growth by Modulating Apoptosis and Autophagy via PI3K/AKT/mTOR and MAPK Pathways.International journal of molecular sciences · 2026Article
- Synergistic Interactions of Anthraquinones with Conventional Cancer Therapies.Combinatorial chemistry & high throughput screening · 2026Review
- A Multidimensional Approach to Sciatica Management Through Ayurveda.Journal of pharmacy & bioallied sciences · 2025Article
- Recent advancement in molecular pathways and receptor targeting using natural products for wound healing activity.Inflammopharmacology · 2025Review
- Natural Compounds That Target Glioma Stem Cells.NeuroSci · 2025Review
- Herbomineral Medicine Peedanil Gold Exerts Analgesia in Neuropathy by Moderating Inflammatory Response and TRP Channel Expression in Sprague Dawley Rat Surgical Chronic Constriction Injury Model.Pain research & management · 2025Article
- From bench to bedside, boswellic acids in anti-inflammatory therapy - mechanistic insights, bioavailability challenges, and optimization approaches.Frontiers in pharmacology · 2025Review
- Regulating the regulators: long non-coding RNAs as autophagic controllers in chronic disease management.Journal of biomedical science · 2024Review
- Principles and Therapeutics ofJournal of pharmacy & bioallied sciences · 2024Review
- Inhibition of intestinal inflammation and fibrosis by Scutellaria Baicalensis georgi and Boswellia serrata in human epithelial cells and fibroblasts.Immunity, inflammation and disease · 2024Article
- Pharmacological and immunomodulatory modes of action of medically important phytochemicals against arthritis: A molecular insight.Molecular biology reports · 2024Review
- Exploring the nexus of nuclear receptors in hematological malignancies.Cellular and molecular life sciences : CMLS · 2024Review
- Exploring the Promising Role of Guggulipid in Rheumatoid Arthritis Management: An In-depth Analysis.Current rheumatology reviews · 2024Review
- Scirpusin B isolated from3 Biotech · 2024Article
- Integrating Network Pharmacology and Molecular Docking Approach to Elucidate the Mechanism ofBioinformatics and biology insights · 2024Article
- Natural compounds targeting nuclear receptors for effective cancer therapy.Cancer metastasis reviews · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive research during last 2 decades has revealed that most drugs discovered today, although costs billions of dollars for discovery, and yet they are highly ineffective in their clinical response. For instance, the European Medicines Agency has approved 68 anti-cancer drugs, and out of which 39 has reached the market level with no indication of increased survival nor betterment of quality of life. Even when drugs did improve survival rate compared to available treatment strategies, most of these were found to be clinically insignificant. This is a fundamental problem with modern drug discovery which is based on thinking that most chronic diseases are caused by alteration of a single gene and thus most therapies are single gene-targeted therapies. However, extensive research has revealed that most chronic diseases are caused by multiple gene products. Although most drugs designed by man are mono-targeted therapies, however, those designed by "mother nature" and have been used for thousands of years, are "multi-targeted" therapies. In this review, we examine two agents that have been around for thousands of years, namely "guggul" from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.